Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 392

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 392
---
10.7 million. This intangible asset is amortized on a straight-line basis over 15 years. Amortization of intangibles for two Successor periods presented are consistent on annualized basis. Other income (expense)

|                                   |     | Year Ended December 31, 
                    2024 |     |            2023 |     |              |
|:----------------------------------|:----|------------------------:|:----|----------------:|:----|-------------:|
|                                   |     |               Successor |     |       Successor |     |  Predecessor |
| (Dollars in thousands)            |     |            January 1 to 
             December 31 |     | September 28 to 
     December 31 |     | January 1 to 
 September 27 |
| Other income (expense), net:      |     |                         |     |                 |     |              |
| Interest income                   |     |                      $— |     |              $— |     |          $66 |
| Interest expense                  |     |                  -1,878 |     |            -360 |     |            — |
| Other income (expense)            |     |                       2 |     |             -39 |     |           11 |
| Total other income (expense), net |     |                $(1,876) |     |          $(399) |     |          $77 |

221

#### TABLE OF CONTENTS
Interest income was zero during the year ended December 31, 2024 (Successor), a decrease of $66 thousand, or (100)%, compared to a sum of $66 thousand and zero for the period from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor), respectively. The Company had no interest income during the Successor periods as all cash and short-term investments are managed by the Parent company.

Interest expense was $1.9 million during the year ended December 31, 2024 (Successor), an increase of $1.5 million compared to a sum of zero and $360 thousand for the period from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor), respectively. Interest expense is attributable to a long-term liability to Reedy